ABSTRACT BACKGROUND Despite standard statin therapy, a majority of patients retain a high "residual risk" of cardiovascular events.
A detailed protocol of the PRECISE-IVUS trial was described previously (7) . Lipid profiles and other biomarker levels were measured at baseline and follow-up at 9 to 12 months (analyzed by SRL Co., Ltd., Tokyo, Japan) at participating institutions or general physician clinics that conducted medical examinations and blood testing.
Participating clinicians were asked to continue administration of the allocated drugs in accordance Final IVUS assessed before 9 months or after 12 months from randomization (8) Changed to another statin (1) Quit taking study drugs (2) IVUS not analyzable (6) Did not complete endpoint assessment: 21 Final IVUS assessed before 9 months or after 12 months from randomization (7) Changed to another statin (3) Quit taking study drugs (2) Added ezetimibe (1)
Protocol Violations: 13
IVUS not performed (16) IVUS not analyzable (4)
Did not complete endpoint assessment: 20
Patients were randomized by treatment group and also followed by presentation. ACS ¼ acute coronary syndrome(s); IVUS ¼ intravascular ultrasound; L ¼ atorvastatin alone group; LZ ¼ atorvastatin plus ezetimibe group; SAP ¼ stable angina pectoris.
with the previously described randomization and titration protocol until the study's end. Serial IVUS and coronary angiography were performed at baseline and again at 9-to 12-month follow-up at participating CV centers. Safety was monitored throughout the study and evaluated by periodic medical examination and laboratory tests at 3, 6, and 9 to 12 months after enrollment. On the basis of expert consensus (9), the primary efficacy endpoint was the absolute change in percent atheroma volume (PAV) of the coronary selected target segment from baseline to follow-up. The PAV was calculated as follows:
IVUS
where EEM CSA is the cross-sectional area of the EEM border, and the lumen CSA is the cross-sectional area of the lumen border. For PAV, the summation of the EEM CSA minus the lumen CSA was performed first.
This value was then divided by the summation of the EEM CSA, which was finally multiplied by 100. The absolute change in PAV was calculated as the PAV at 9-to 12-month follow-up minus the PAV at baseline.
The secondary efficacy endpoint was percent change in normalized total atheroma volume (TAV), which was calculated as follows: The per-protocol dataset analysis was also specified if the enrolled patients completely met the inclusion and exclusion criteria and were followed according to protocol. If patients received the study drugs at least once, they were included in the safety analysis. The number of adverse events was assessed to determine safety profiles. A p value <0.05 was considered significant.
The PRECISE-IVUS trial aimed to evaluate whether the effect of atorvastatin/ezetimibe on coronary atheroma regression would not be inferior to that of atorvastatin monotherapy. A detailed structure of statistical analyses in the present study was described (13) 4 (8) 4 (8) 11 (22) 9 (17) History of stroke 10 (10)* 1 (1) 4 (8) 1 (2) 6 (12)* 0 
Nitrates 6 (6) 14 (14) 5 (10) 4 (8) 1 (2) elsewhere (7) . According to the pre-specified noninferiority margin and sample size calculation, investigators established a noninferiority margin of 3%, and calculated that 100 subjects were needed in each group, with an alpha level of 5% that gave power of 80%. A key secondary objective was to determine whether the atorvastatin/ezetimibe combination was superior to atorvastatin monotherapy with respect to the nominal change in coronary PAV. There were no significant differences in demographic characteristics or baseline medication use between the 2 treatment groups, except for history of stroke and frequency of nitrate use ( Table 1) .
RESULTS

From
PRECISE-IVUS investigators enrolled patients with
both ACS and SAP; eventually, one-half of the study patients were assigned to the ACS cohort; the others to the SAP cohort. The majority of patients (78%) were men, and 30% of the total study patients had diabetes. Among those with ACS, the clinical presentation was ST-segment elevation myocardial infarction in 51%. In terms of concomitant medication, the majority of patients were treated with optimal medical therapy in addition to lipid-lowering study drugs.
Baseline and follow-up laboratory data are shown in Table 2 . Although LDL-C levels were similar between the 2 groups at baseline, LDL-C level was significantly lower at 9 to 12 months in the LZ group than in the L group (p < 0.001), and the dual lipid-lowering strategy showed more remarkable reduction of LDL-C level than atorvastatin monotherapy during the study Values are mean AE SD or median (IQR).
HDL-C ¼ high-density lipoprotein cholesterol; HMW ¼ high molecular weight; hs-CRP ¼ high-sensitivity C-reactive protein; LDL-C ¼ low-density lipoprotein cholesterol; MDA-LDL ¼ malondialdehydemodified LDL; RLP-C ¼ remnant like particles cholesterol; sdLDL-C ¼ small-dense LDL-C; TC ¼ total cholesterol; other abbreviations as in Table 1 .
with the L group. Although there was no difference between the 2 groups in percent change of highsensitivity C-reactive protein, cholesterol absorption markers-campesterol, sitosterol, campesterol-tocholesterol ratio, sitosterol-to-cholesterol ratio, and campesterol-to-lathosterol ratio-were all significantly decreased in the LZ group from baseline to 9 to 12 months of follow-up. Those levels were significantly increased in the L group. Table 3 shows the IVUS efficacy endpoints at each time point and the serial changes (Central Illustration). Analyses were performed on data from the full analysis set population ( Figure 1) ; comparison of the primary endpoint was analyzed as part of hierarchical sequence testing (starting with testing of the primary endpoint for noninferiority, and then testing superiority) to control for the type I error. The primary endpoint (noninferiority of the LZ to the L group in absolute change in PAV) was proved ( Figure 2) , with a mean difference of drug effects on absolute change in PAV of -1.538%
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(95% confidence interval [CI]: -3.079% to 0.003%).
The upper limit of the 95% CI did not exceed the predefined noninferiority margin of 3% (7). For superiority, the absolute change in PAV decreased by -1.4% For percent change in TAV normalized , a secondary IVUS endpoint, the effect was more favorable in the LZ group than in the L group (-6.6%; 95% CI: -12.6% to 0.2% vs. -1.4%; 95% CI: -6.7% to 4.4%; p < 0.001).
For TAV normalized , a significantly greater proportion of the LZ group patients had disease regression (75% vs.
58%; p ¼ 0.02).
With regard to vessel remodeling during follow-up, the vessel volume of the target segment analyzed was negatively remodeled in the LZ group versus the L group, although the lumen volume serial change was comparable between the groups. TAV ¼ total atheroma volume; other abbreviations as in Table 1 .
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Main Results of the PRECISE-IVUS Trial
Similar results were confirmed even in the "per protocol set" cohort (Online Table 1 
LDL-C. Among cholesterol absorption markers, the campesterol-to-cholesterol ratio tended to be lower in the regression group versus the progression group. As shown in Figure 4 , relationships between these biomarkers and the absolute change in PAV were evaluated using linear regression analysis in the full study, ACS, and SAP cohorts. Similar to a recent IVUS study (10) , there were no strong correlations between The atorvastatin/ezetimibe (LZ) group was noninferior to the atorvastatin-alone (L) group in terms of the primary endpoint, which was the absolute change in percent atheroma volume (PAV). m LZ -m L indicates the difference of drug effects on absolute change in PAV, where m LZ represents the absolute change in PAV in the LZ group and m L represents that of the L group. 
Main Results of the PRECISE-IVUS Trial these biomarkers and absolute change in PAV. In the achieved LDL-C level at follow-up ( Figures 4A to 4C) and the percent change in the campesterol-tocholesterol ratio during follow-up ( Figures 4D to 4F ), despite the weak correlation, the steeper positive slope of the regression line was noted more in the ACS cohort than the SAP cohort, which suggested plaque development reversibility in patients with ACS.
Online Table 2 shows the clinical events, laboratory abnormalities, and reasons for study drug discontinuation. Both strategies were well tolerated throughout the study. For both groups, the frequency of CV events was similar, the rate of abnormal laboratory values was low, and the rate of target lesion/ vessel revascularization was similar. Tsujita et al.
Main Results of the PRECISE-IVUS Trial progression ( Table 4) 
PERSPECTIVES COMPETENCY IN MEDICAL KNOWLEDGE:
Combination therapy with atorvastatin plus ezetimibe was associated with greater coronary plaque regression than atorvastatin alone in patients who underwent PCI.
TRANSLATIONAL OUTLOOK: Additional studies are needed to ascertain the mechanism by which ezetimibe accelerates plaque regression in this situation compared with statin monotherapy.
